Provided by Tiger Fintech (Singapore) Pte. Ltd.

Repare Therapeutics Inc.

1.43
+0.02001.42%
Post-market: 1.430.00000.00%17:16 EDT
Volume:264.17K
Turnover:380.77K
Market Cap:60.79M
PE:-0.72
High:1.48
Open:1.41
Low:1.40
Close:1.41
Loading ...

LifeSci Capital Keeps Their Hold Rating on Repare Therapeutics (RPTX)

TIPRANKS
·
02 May

Repare Therapeutics Inc. Enters Partnership with DCx Biotherapeutics to Out-License Discovery Platforms

Reuters
·
01 May

DCx Biotherapeutics Partners with Repare Therapeutics to Accelerate Development of Multi-Modal Antibody Drug Conjugates

Reuters
·
01 May

Repare Therapeutics Announces Out-Licensing of Its Discovery Platforms to Dcx Biotherapeutics

THOMSON REUTERS
·
01 May

Repare Therapeutics Announces Out-Licensing of its Discovery Platforms to DCx Biotherapeutics

Business Wire
·
01 May

Repare Therapeutics Announces Six Abstracts Accepted for Presentation at AACR Annual Meeting 2025

Business Wire
·
26 Apr

BRIEF-Repare Therapeutics - Steve Forte, Executive Vice President And Chief Financial Officer, Appointed As President, Chief Executive Officer And Director

Reuters
·
01 Apr

Repare Therapeutics Appoints Steve Forte as CEO to Succeed Lloyd Segal

MT Newswires Live
·
01 Apr

Repare Therapeutics Names Forte as President, CEO

Dow Jones
·
01 Apr

Repare Therapeutics- Exploring Strategic Alternatives and Partnerships Across Portfolio, Including for Lunresertib & Camonsertib

THOMSON REUTERS
·
01 Apr

Repare Therapeutics - Steve Forte, Executive Vice President and Chief Financial Officer, Appointed as President, Chief Executive Officer and Director

THOMSON REUTERS
·
01 Apr

Repare Therapeutics: Lloyd M. Segal Resigned as President, CEO and Director

THOMSON REUTERS
·
01 Apr

Repare Therapeutics Announces Leadership Transitions

Business Wire
·
01 Apr

What Makes Repare Therapeutics (RPTX) a New Buy Stock

Zacks
·
12 Mar

Strategic Pipeline Focus and Financial Stability Support Buy Rating for Repare Therapeutics

TIPRANKS
·
07 Mar

Repare Therapeutics Full Year 2024 Earnings: EPS Beats Expectations, Revenues Lag

Simply Wall St.
·
04 Mar

LifeSci Capital Sticks to Its Hold Rating for Repare Therapeutics (RPTX)

TIPRANKS
·
04 Mar

Repare Therapeutics Restructures and Focuses on Key Clinical Trials

TIPRANKS
·
04 Mar

Repare Therapeutics Q4 2024 GAAP EPS $(0.67) Beats $(0.79) Estimate, $152.8M In Cash And Cash Equivalents And Marketable Securities Provides Runway To Late-2027

Benzinga
·
03 Mar

BRIEF-Repare Therapeutics FY EPS USD -2

Reuters
·
03 Mar